We want to reduce the
transmission of resistant bacteria
in neonatal intensive care units
across Europe and globally.

We want to reduce the
transmission of resistant bacteria

in neonatal intensive care units
across Europe and globally

Why this project

Nearly 1 in 10 newborns in Europe is admitted to a neonatal intensive care unit in the first days of life – that is around 400,000 admissions every year.

While care in a neonatal unit results in a greater chance of survival in newborns with serious illness, it also increases the risk of exposure to bacteria from the hospital environment. These can cause serious infections in babies, which are commonly resistant to many routinely used antibiotics.

The NeoIPC response

NeoIPC will identify best practices for the prevention of infections and surveillance of resistant bacteria in neonatal intensive care units in Europe. By conducting a clinical trial, the project will assess the safety and effectiveness of one or more specific, lowcost and simple interventions to prevent transmissions and infections with hospital bacteria in newborns.

Surveillance

Within the framework of the NeoIPC project, we have developed a surveillance system to contribute to the prevention and control of healthcare-associated infections in neonatology.

Governance

Led by the University of Padova, NeoIPC project consists of thirteen partners representing multiple institutions in Europe and Africa.

Latest project news

NeoDeco Country Investigator Meetings are underway!

On 19 October and on 3 November 2023, the NeoIPC WP2-TRIAL team successfully hosted two NeoDeco Country Investigator Meetings. One took place in Zurich, Switzerland, and the other in Thessaloniki, Greece, marking the beginning of a series of meetings involving the...

read more